Project Grant R41AI191973
Award Date 9/23/25
Completion Date 8/31/26
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
West Chester, PA, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,616 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Shy Therapeutics, LLC to develop a novel class of small molecule antifungal therapies. The project aims to identify and optimize new chemical compounds with potent activity against drug-resistant fungal strains such as Cryptococcus neoformans and Candida auris. Key objectives include using structure-activity relationship...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the CFDA 93.855 Allergy and Infectious Diseases Research program, awarded a $300,000 Project Grant to Life Pharms Inc. on September 19, 2025. The grant supports the development of a novel antifungal drug, LP10581, to address the growing public health crisis of invasive, drug-resistant fungal infections. The project aims to further research and testing of this novel compound, which has shown promising in vitro and in vivo...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $265,650 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to HMH Hospitals Corporation, doing business as Hackensack University Medical Center, to study the effects of antifungal drug treatment and immune dysfunction on the evolutionary dynamics of the gut-colonizing fungus Candida glabrata. This research aims to provide insights into the population dynamics and drug...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $245,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The grant will fund the development of a novel mouse model to study the immunological consequences of neonatal colonization with the commensal fungus Candida albicans. The research aims to characterize oral mucosal immune cell populations in...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $857,215 to HMH Hospitals Corporation (doing business as Hackensack University Medical Center) to conduct research on how the fungal pathogen Candida albicans adapts to different host environments, such as the oral and systemic infection niches. The research aims to decipher how the fungal acetylome, regulated by the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $511,553 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Maryland, Baltimore. The grant funding will support the development of an oral immunotherapy using engineered probiotic yeast to deliver neutralizing antibodies against the Clostridioides difficile (C. diff) surface protein CWP84. This novel approach aims to reduce C. diff colonization and spore...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,193,457 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Massachusetts Medical School (UMASS Medical) to produce, validate, and provide relevant fungal antigens to the scientific community. The funding will support the manufacturing of crude antigenic preparations from various fungal pathogens, as well as the recombinant production and testing of 36...
- This federal Project Grant award for $489,500 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research focused on identifying non-conserved regulatory elements in the cell wall stress response of the fungus Candida albicans and testing non-conserved protein regions to discover novel antifungal drug targets. Key objectives include characterizing a cell wall stress...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $164,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Albany Medical College. The grant supports research to identify and characterize additional conformer-specific anti-I-A monoclonal antibodies (mAbs) to study the structure and function of MHC class II molecules, which are important for T cell-mediated immune responses. The research aims to address limitations in existing...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $806,208 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Weill Medical College of Cornell University. The project, titled "Spatial Omics to Understanding HBV Control in People with HIV Coinfection," will leverage cutting-edge spatial proteomic and transcriptomic technologies to analyze the impact of HIV-related immune suppression and restoration on the...